The battle between two medical giants, Brigham and Dana-Farber, is heating up, and it’s patients, staff, and the future of cancer care in Boston that hang in the balance. What happens when a decades-long partnership turns into a high-stakes competition? This is the question looming over the recent split between Brigham and Dana-Farber, a breakup that’s becoming messier by the day. But here’s where it gets controversial: Brigham’s corporate parent, Mass General Brigham, has not only opened its own cancer institute but is now planning to phase out Dana-Farber physician assistants (PAs) entirely by the end of the year. These PAs, though employed by Dana-Farber, have been working under contract at Brigham’s hospital, leaving their employment status in limbo.
In an internal email, Dana-Farber’s chief medical officer, Dr. Craig Bunnell, expressed frustration, stating, ‘This is not the transition approach we were working toward.’ Meanwhile, Mass General Brigham fired back with a bold move, offering these same PAs jobs directly, writing, ‘We want you on our team.’ This tug-of-war over staff is just the tip of the iceberg in a rivalry that’s been simmering for years, fueled by Dana-Farber’s push for its own hospital and Mass General Brigham’s consolidation of its flagship institutions.
But is this competition good for patients, or is it a recipe for a medical arms race? Gary J. Young, a professor of strategic management and health care systems at Northeastern University, warns that this dynamic could lead to skyrocketing health care spending as both institutions invest heavily in technology, staff, and high-priced oncologists. In the long term, this consolidation of cancer care could siphon higher-margin patients away from community hospitals, further destabilizing already fragile institutions.
And this is the part most people miss: While both hospitals publicly claim to prioritize patient care, behind the scenes, they’re locked in a financial and strategic battle. Mass General Brigham, for instance, is already offering extra pay to physician assistants to work at its new cancer unit, while Dana-Farber and Brigham struggle to agree on a transition plan. The bridge that once symbolized their collaboration now feels more like a battleground.
The stakes are staggeringly high. For Brigham, 40% of all surgeries are cancer-related, making this a fight to maintain its dominance in the field. For Dana-Farber, cancer is its business. As both sides announce competing multimillion-dollar donations and initiatives, the question remains: Will patients notice the tension? And how will insurers dictate access to care? Young cautions, ‘They want patients to see care as being largely seamless, but it will be a trick to pull off.’
So, what do you think? Is this competition driving innovation, or is it a costly distraction from the real goal of patient care? Let us know in the comments below. The future of cancer treatment in Boston may depend on it.
